• Publications
  • Influence
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
TLDR
Studying a mouse model of PDA that is refractory to the clinically used drug gemcitabine, it is found that the tumors in this model were poorly perfused and poorly vascularized, properties that are shared with human PDA. Expand
The proteasome: a suitable antineoplastic target
  • J. Adams
  • Biology, Medicine
  • Nature Reviews Cancer
  • 1 May 2004
The proteasome is an abundant multi-enzyme complex that provides the main pathway for degradation of intracellular proteins in eukaryotic cells. As such, it controls the levels of proteins that areExpand
The development of proteasome inhibitors as anticancer drugs.
  • J. Adams
  • Medicine, Biology
  • Cancer cell
  • 1 May 2004
TLDR
Efficacy and safety results from a phase 2 clinical trial contributed to approval of bortezomib for use in patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies and have demonstrated disease progression on their last therapy. Expand
The proteasome: structure, function, and role in the cell.
  • J. Adams
  • Biology, Medicine
  • Cancer treatment reviews
  • 1 May 2003
TLDR
In in vitro and in vivo animal studies, inhibition of the proteasome via bortezomib (VELCADE) had antitumor activity against numerous tumor types either alone or in combination with conventional chemotherapeutic agents; these results provided the rationale for a broad clinical trial program. Expand
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer
TLDR
It is shown that there is no substantial change in the crystal structure of the liganded and unliganded human GHR extracellular domain, and an activation mechanism involving a relative rotation of subunits within a dimeric receptor as a result of asymmetric placement of the receptor-binding sites on the ligand is proposed. Expand
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
TLDR
PS-341 showed activity against refractory multiple myeloma and possibly non-Hodgkin's lymphoma in this study, and merits further investigation in these populations. Expand
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
TLDR
It is demonstrated that targeting PI3Kγ with a selective inhibitor can reshape the tumour immune microenvironment and promote cytotoxic-T-cell-mediated tumour regression without targeting cancer cells directly. Expand
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
TLDR
It is safe and reasonable to recommend treatment with PS341 on the schedule used in this trial at 1.56 mg/m2/dose in Phase II trials, and particular care should be taken with patients with preexisting neuropathy. Expand
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
TLDR
Overall, the drug was well tolerated, with only one grade 4 toxicity (hyponatremia), and the most common grade 3 toxicities were lymphopenia and thrombocytopenia. Expand
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
TLDR
A novel pharmacodynamic assay has shown that bortezomib–mediated proteasome blockade is dose-dependent and reversible, and phase II trials have been initiated for both solid and hematological malignancies. Expand
...
1
2
3
4
5
...